Data released Wednesday shows that per 10,000 people, the rate of infections among persons who have taken either the first or second dose of Bharat Biotech's Covaxin or Serum Institute's Covishield is extremely low
❮ ❯
Skip the startup: Why more entrepreneurs are choosing acquisition
Photo of the day: US Elections: Final Pitch
What sets Asia-Pacific apart from the world?
Tech5: India seeing smartphone 'premiumisation'; at Dow Jones index, Nvidia is in, Intel out, and more
Rohit Bal was 'wildly Indian, a showman, the first to take menswear seriously'
Photo of the day: New York City marathon
We want to be the AI powerhouse of the world: SAP Labs India's Sindhu Gangadharan
The sandwich is still the world's favourite lunchtime dish
The growing scourge of plastic pollution: in numbers
How websites could make more money selling display ads
Tech5: Apple's different stories in China and India, Infosys's market research on AI, and more
Photo of the Day: Pan de Muertos
Photo of the Day: Penguin colony
Photo of The Day: Lit sky for Diwali
Walking with the Veddas in Sri Lanka